What is DiaCarta?
DiaCarta operates at the forefront of translational genomics and personalized diagnostics, with a specialized focus on cancer gene mutation detection. Leveraging proprietary technologies such as XNA and isobDNA, the company excels in the sensitive and accurate identification of genetic alterations. This technological prowess positions DiaCarta as a leader in the precision diagnostic industry, offering a comprehensive suite of diagnostic products and services to healthcare providers and patients globally. Their offerings span tests for various cancers and infectious diseases, all aimed at advancing patient care through precision medicine. DiaCarta actively collaborates with pharmaceutical, biopharmaceutical companies, and clinicians to enhance diagnostic capabilities and treatment strategies.
How much funding has DiaCarta raised?
DiaCarta has raised a total of $53M across 2 funding rounds:
Series A
$8M
Series B
$45M
Series A (2015): $8M with participation from BVCF Management
Series B (2018): $45M led by Fortune Fountain Capital and Good Health Capital
Key Investors in DiaCarta
Fortune Fountain Capital
Fortune Fountain Capital is a financial group engaging in financial services, wealth management, and principal investment, identifying attractive opportunities for long-term strategic holding. They offer a wide range of financial products and services to high-net-worth individuals and distinguished families.
Good Health Capital
Good Health Capital focuses on investing in acute care hospitals, surgery centers, and HMOs in the USA, UK, and Continental Europe, partnering with healthcare systems and international capital sources. Their seasoned team specializes in healthcare, structured finance, and real estate.
BVCF Management
BioVeda China Fund (BVCF) is a biomedical venture capital firm based in China, focused on creating and developing innovative Chinese life sciences companies. They employ a forward-looking investment strategy leveraging insights into technology, policy, and market opportunities.
What's next for DiaCarta?
The recent major strategic investment signifies a pivotal moment for DiaCarta, indicating a transition towards scaling its operations and potentially expanding its market reach. This enterprise-level backing suggests confidence from investors in DiaCarta's long-term vision and its capacity to capitalize on the growing demand for advanced diagnostic solutions. Future strategic initiatives are likely to involve further development of their innovative technologies, broadening their product portfolio, and forging new partnerships within the healthcare ecosystem to solidify their position in the precision medicine sector.
See full DiaCarta company page
